Canine Patient Recruitment

As of January 12, 2017

If you would like additional information regarding a clinical trial, please contact us at:

Phone: (765) 496-9715
Fax: (765) 496-1108

If you believe your pet is eligible for a specific study, we recommend that you contact your veterinarian and request a referral. However, a referral may not be required to participate in some clinical trials.

To make an appointment at the Small Animal Hospital please call (765) 494-1107.


Canine Aggression Study in Labrador Retriever, Beagle and Standard Poodle

  • Description: This study is to compare genetic and behavior information between human directed aggressive dogs and non-aggressive (to both humans and animals) dogs in three different breeds to see if potential genetic and/or biomarkers may be identified.
  • Eligibility: Pure bred Labrador Retrievers, Beagles, or Standard Poodles that are either affected dogs (human aggressive dogs) or control dogs (no aggression toward humans or animals) are eligible.
  • Financial Incentive: No cost for collection of samples (blood). Blood collection can also be performed at the primary veterinarian office and shipped to us (cost for blood collection and shipping will be covered).
  • Primary Investigator: Dr. Niwako Ogata

For more information or to contact us

Separation Anxiety Disorder and Non-Separation Anxiety Disorder Dogs

  • Description: A study to develop biomarkers to assess anxiety disorders in dogs.
  • Eligibility: Clinically healthy dogs that must be neutered/spayed and between the ages of 1.5-7 years old. All participants (either separation anxiety dogs or non-anxious dogs) will be pre-screened for eligibility through a questionnaire and a 30-minute video clip at home.
  • Financial Incentive: No cost for collection of samples (blood).
  • Primary Investigator: Dr. Niwako Ogata

For more information or to contact us

Behavioral and Physiological Responses in Dogs Under Social Anxiety

  • Description: A study to compare behavioral and physiological responses to identify the dogs at risk of social anxiety (both home and an exam room environment).
  • Eligibility: Clinically healthy dogs that must be neturered/spayed and between the ages of 1-13 years old can participate in the study.
  • Financial Incentive: No cost for collection of samples (saliva).
  • Primary Investigator: Dr. Niwako Ogata

For more information or to contact us


MRI for Dogs Suspected to Have Brain Tumors

  • Description: A study to develop MRI in the diagnosis of dogs with brain tumors.
  • Eligibility: Any dog that is suspected to be suffering from a brain tumor. Examination by the Neurology & Neurosurgery service must confirm the suspicion of a brain tumor and eligibility for the study. Bloodwork and chest radiographs (from within the last month) must have already been performed – these may be performed at the referring veterinarian office before the appointment at Purdue.
  • Financial Incentive: The cost of the MRI is significantly reduced.
  • Primary Investigator: Dr. Timothy Bentley

For more information or to contact us

Surgery and Metronomic Chemotherapy for Brain (Glioma) Tumors in Dogs

  • Description: Combination surgery and chemotherapy for glioma brain tumors in dogs, including a repeat MRI at 3 months. Samples to test the chemotherapy concentrations will be taken during the study. 
  • Eligibility: Dogs that have been tentatively diagnosed with a glioma brain tumor by MRI. Dr. Bentley must confirm the suspicion of a glioma by the MRI before enrollment.  Chest radiographs and bloodwork must also have been performed (within the last month). 
  • Financial Incentives: The brain tumor surgery, the chemotherapy, the bloodwork to monitor the chemotherapy and the repeat MRI will all be provided at no charge. 
  • Primary Investigators: Dr. Timothy Bentley
  • Additional information is available on the Canine Brian Tumor Research Page

For more information or to contact us


Vemurafenib Treatment in Dogs with Bladder Cancer, i.e. Transitional Cell Carcinoma (TCC)

  • Description: The purpose of this study is to determine the anti-tumor effects, the toxicity (or lack thereof), and the appropriate dose of Vemurafenib in dogs with TCC.  Vemurafenib is a drug that kills tumor cells that have a very precise mutation. The goal is to improve the outlook for pet dogs and people with cancer. 
  • Eligibility
    • Biopsy proof of TCC
    • Confirmed BRAF V600E mutation in TCC cells in the urine (a urine test)
    • Measurable cancer lesions that can be followed to assess antitumor effects
    • Acceptable “performance status” (the dogs still feels OK)
    • Expected survival ≥ 6  weeks
    • Acceptable kidney function (serum creatinine ≤ 2mg/dl)
  • Financial Incentive: The pet owner is required to pay $250.00 per month for the expenses incurred in the Purdue University Veterinary Teaching Hospital (PUVTH) related to the treatment and monitoring. The funding agency will cover the remainder of the cost related to the Vemurafenib treatment and monitoring in the PUVTH. Any work done outside of the PUVTH or any expenses not related to the Vemurafenib treatment must be paid by the pet owner. 
  • Primary Investigator: Dr. Deborah Knapp

For more information or to contact us


Dogs With Dry Eye Disease

  • Description: A study to evaluate the injection of stem cells derived from the dog's own fat into the diseased lacrimal glands to return functional tearing.
  • Eligibility: Dogs with documented dry eye that have responded poorly to standard treatment of topical cyclosporine or tacrolimus. Some dogs with extremely chronic lack of any tear production may not qualify for the study.
  • Financial Incentive: Reduced cost of laboratory preparation of stem cells.
  • Primary Investigator: Dr. Jean Stiles

For more information or to contact us

Golden Retriever Pigmentary Uveitis (PU)

  • Description: A study to better understand the disease progression of PU and establish a DNA bank of samples from both affected and normal Golden Retrievers.
  • Eligibility: Any purebred Golden Retriever.
  • Financial Incentive: There is no compensation for participation in this study. However, the ocular examination is performed at no cost to you.
  • Primary Investigator: Dr. Wendy Townsend

For more information or to contact us


Polyarthritis – Folate-receptor Targeted Drug Delivery

  • Description: A study to evaluate a new folate-receptor drug complex for the treatment of immune mediated polyarthritis in dogs. The drug has strong anti-inflammatory activity, similar to the new rheumatoid arthritis drugs for humans.
  • Eligibility: Dogs with naturally occurring immune mediated polyarthritis.
  • Financial Incentive: All costs related to the diagnosis and rechecks through the 16 week recheck will be reimbursed to the owner. The owner is responsible for the cost of the initial visit for diagnosis. During this visit, the scintigraphy will be done free of charge. Once the diagnosis of immune mediated polyarthritis is made, the owner will be advised about eligibility for enrollment.
  • Primary Investigator: Dr. Gert Breur

For more information or to contact us

    Purdue University College of Veterinary Medicine, 625 Harrison Street, West Lafayette, IN 47907, (765) 494-7607

    © 2017 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by PVM Web Communications

    If you have trouble accessing this page because of a disability, please contact PVM Web Communications at